82 related articles for article (PubMed ID: 26361996)
1. Comparative proteome analysis across non-small cell lung cancer cell lines.
Grundner-Culemann K; Dybowski JN; Klammer M; Tebbe A; Schaab C; Daub H
J Proteomics; 2016 Jan; 130():1-10. PubMed ID: 26361996
[TBL] [Abstract][Full Text] [Related]
2. Glycoproteomic Approach Identifies KRAS as a Positive Regulator of CREG1 in Non-small Cell Lung Cancer Cells.
Clark DJ; Mei Y; Sun S; Zhang H; Yang AJ; Mao L
Theranostics; 2016; 6(1):65-77. PubMed ID: 26722374
[TBL] [Abstract][Full Text] [Related]
3. Quantitative Secretomic Analysis Identifies Extracellular Protein Factors That Modulate the Metastatic Phenotype of Non-Small Cell Lung Cancer.
Hu R; Huffman KE; Chu M; Zhang Y; Minna JD; Yu Y
J Proteome Res; 2016 Feb; 15(2):477-86. PubMed ID: 26736068
[TBL] [Abstract][Full Text] [Related]
4. Establishment and comparative characterization of novel squamous cell non-small cell lung cancer cell lines and their corresponding tumor tissue.
Gottschling S; Jauch A; Kuner R; Herpel E; Mueller-Decker K; Schnabel PA; Xu EC; Muley T; Sültmann H; Bender C; Granzow M; Efferth T; Hoffmann H; Dienemann H; Herth FJ; Meister M
Lung Cancer; 2012 Jan; 75(1):45-57. PubMed ID: 21684623
[TBL] [Abstract][Full Text] [Related]
5. Triple SILAC quantitative proteomic analysis reveals differential abundance of cell signaling proteins between normal and lung cancer-derived exosomes.
Clark DJ; Fondrie WE; Yang A; Mao L
J Proteomics; 2016 Feb; 133():161-169. PubMed ID: 26739763
[TBL] [Abstract][Full Text] [Related]
6. Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line.
Wu Q; Cheng Z; Zhu J; Xu W; Peng X; Chen C; Li W; Wang F; Cao L; Yi X; Wu Z; Li J; Fan P
Sci Rep; 2015 Mar; 5():9520. PubMed ID: 25825284
[TBL] [Abstract][Full Text] [Related]
7. Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors.
Schweppe DK; Rigas JR; Gerber SA
J Proteomics; 2013 Oct; 91():286-96. PubMed ID: 23911959
[TBL] [Abstract][Full Text] [Related]
8. CHCHD2 Is Coamplified with EGFR in NSCLC and Regulates Mitochondrial Function and Cell Migration.
Wei Y; Vellanki RN; Coyaud É; Ignatchenko V; Li L; Krieger JR; Taylor P; Tong J; Pham NA; Liu G; Raught B; Wouters BG; Kislinger T; Tsao MS; Moran MF
Mol Cancer Res; 2015 Jul; 13(7):1119-29. PubMed ID: 25784717
[TBL] [Abstract][Full Text] [Related]
9. Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.
Chang JW; Liu HP; Hsieh MH; Fang YF; Hsieh MS; Hsieh JJ; Chiu YT; Tsai HY; Chen YH; Chen YT; Hsu HY; Chen YT; Tsai SF; Chen YR; Hsi BL; Huang SF
Lung Cancer; 2008 Sep; 61(3):328-39. PubMed ID: 18304690
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
11. Primary tumor xenografts of human lung adeno and squamous cell carcinoma express distinct proteomic signatures.
Wei Y; Tong J; Taylor P; Strumpf D; Ignatchenko V; Pham NA; Yanagawa N; Liu G; Jurisica I; Shepherd FA; Tsao MS; Kislinger T; Moran MF
J Proteome Res; 2011 Jan; 10(1):161-74. PubMed ID: 20815376
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer.
Zhen Q; Liu J; Gao L; Liu J; Wang R; Chu W; Zhang Y; Tan G; Zhao X; Lv B
Cytogenet Genome Res; 2015; 146(1):1-8. PubMed ID: 26184032
[TBL] [Abstract][Full Text] [Related]
13. Proteome screening of pleural effusions identifies IL1A as a diagnostic biomarker for non-small cell lung cancer.
Li Y; Lian H; Jia Q; Wan Y
Biochem Biophys Res Commun; 2015 Feb; 457(2):177-82. PubMed ID: 25554695
[TBL] [Abstract][Full Text] [Related]
14. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
15. Sequence-dependent antiproliferative effects of gefitinib and docetaxel on non-small cell lung cancer (NSCLC) cells and the possible mechanism.
Chen B; Zheng J; Zeng Y; Li B; Xie B; Zheng J; Zhou J; Zhang W
PLoS One; 2014; 9(12):e114074. PubMed ID: 25474307
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
Eberhard DA; Johnson BE; Amler LC; Goddard AD; Heldens SL; Herbst RS; Ince WL; Jänne PA; Januario T; Johnson DH; Klein P; Miller VA; Ostland MA; Ramies DA; Sebisanovic D; Stinson JA; Zhang YR; Seshagiri S; Hillan KJ
J Clin Oncol; 2005 Sep; 23(25):5900-9. PubMed ID: 16043828
[TBL] [Abstract][Full Text] [Related]
17. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
Stabile LP; Lyker JS; Gubish CT; Zhang W; Grandis JR; Siegfried JM
Cancer Res; 2005 Feb; 65(4):1459-70. PubMed ID: 15735034
[TBL] [Abstract][Full Text] [Related]
18. Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.
Ota K; Azuma K; Kawahara A; Hattori S; Iwama E; Tanizaki J; Harada T; Matsumoto K; Takayama K; Takamori S; Kage M; Hoshino T; Nakanishi Y; Okamoto I
Clin Cancer Res; 2015 Sep; 21(17):4014-21. PubMed ID: 26019170
[TBL] [Abstract][Full Text] [Related]
19. Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations.
Farina G; Longo F; Martelli O; Pavese I; Mancuso A; Moscetti L; Labianca R; Bertolini A; Cortesi E; Farris A; Fagnani D; Locatelli MC; Valmadre G; Ardizzoia A; Tomirotti M; Rulli E; Garassino MC; Scanni A
Clin Lung Cancer; 2011 Mar; 12(2):138-41. PubMed ID: 21550561
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-2 protein levels are independent of epidermal growth factor receptor expression or activation in operable non-small cell lung cancer.
Richardson CM; Richardson D; Swinson DE; Swain WA; Cox G; O'Byrne KJ
Lung Cancer; 2005 Apr; 48(1):47-57. PubMed ID: 15777970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
